<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03655457</url>
  </required_header>
  <id_info>
    <org_study_id>22032018</org_study_id>
    <nct_id>NCT03655457</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Surfaktant in Preterm Infants by Lung Ultrasound</brief_title>
  <official_title>Evaluation of the Efficacy of Different Surfactant Preparations in Preterm Infants by Lung Ultrasound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zekai Tahir Burak Women's Health Research and Education Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zekai Tahir Burak Women's Health Research and Education Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the lung ultrasound scores after two different natural surfactant administration
      as a parameter reflecting lung inflation. Poractant alfa decreases lung ultrasound scores as
      efficient as beractant treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outcomes:

      Improvement of Lung usg scores after surfactanct and the difference between groups at
      different time points (2nd and 6hr).

      Secondary outcome:

      The correlation between lung usg scores and clinical scores (silverman scores), FiO2 and PCO2
      levels, failure of weaning to noninvasive ventilation after surfactant Preterm infants of 32
      gestational weeks and below, who admit to the NICU with signs of respiratory distress,
      treated with non invasive or mechanical ventilation and require surfactant treatment in 6
      hours of life will be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 21, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung usg scores</measure>
    <time_frame>first days</time_frame>
    <description>Evaluation of Lung Usg Scores in infants treated with surfactant in the first six hours (Brat lung usg scores). Each item scored 0-3. (0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.)
- Higher values represent a worse outcome</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Lung Ultrasound Scores</condition>
  <arm_group>
    <arm_group_label>group 1 Poractant alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Poractant alfa generic name: curosurf 120 and 240 mg flk dosage: 200 mg/ kg intratracheal application frequency and duration: in the first two hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2 beractant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>beractant generic name: survanta 8 cc flk dosage: 4 cc/ kg intratracheal application frequency and duration: in the first two hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>group 1 Poractant alfa</intervention_name>
    <description>Comparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.</description>
    <arm_group_label>group 1 Poractant alfa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>group 2 beractant</intervention_name>
    <description>lComparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.</description>
    <arm_group_label>group 2 beractant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm infants of 32 gestational weeks and below, who admit to the NICU with signs of
             respiratory distress, treated with non invasive or mechanical ventilation and require
             surfactant treatment in 6 hours of life will be enrolled.

        Exclusion Criteria:

          -  major congenital anomalies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evrim Alyamaç Dizdar, MD</last_name>
    <role>Study Director</role>
    <affiliation>zekai tahir burak matarnity teaching hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Davut Bozkaya, MD</last_name>
    <phone>+905053197531</phone>
    <email>drbozkaya@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Evrim Alyamaç Dizdar, MD</last_name>
    <phone>+905063668840</phone>
    <email>drevrimdizdar@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zekai Tahir Burak Matarnity Teaching</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davut Bozkaya, MD</last_name>
      <phone>+905053197531</phone>
      <email>drbozkaya@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Şebnem Özyer, MD</last_name>
      <phone>+903123065272</phone>
      <email>sebnemsenozyer@yahoo.com,</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>December 9, 2018</last_update_submitted>
  <last_update_submitted_qc>December 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung</keyword>
  <keyword>RDS</keyword>
  <keyword>Surfaktant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poractant alfa</mesh_term>
    <mesh_term>Beractant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

